Version in force 1 December 2018

Previous version, detected 13 August 2026 02008R1272-20180301 → this version, in force 1 December 2018 02008R1272-20181201

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 161 unchanged lines … Note J: The classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w benzene (EINECS No 200-753-7). This note applies only to certain complex coal- and oil-derived substances in Part 3. Note K: The classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w 1,3-butadiene (EINECS No 203-450-8). If the substance is not classified as a carcinogen or mutagen, at least the precautionary statements (P102-)P210-P403 (Table 3.1) or the S-phrases (2-)9-16 (Table 3.2) should apply. This note applies only to certain complex oil-derived substances in Part 3. The classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w 1,3-butadiene (Einecs No 203-450-8). If the substance is not classified as a carcinogen or mutagen, at least the precautionary statements (P102-)P210-P403 should apply. This note applies only to certain complex oil-derived substances in Part 3. Note L: The classification as a carcinogen need not apply if it can be shown that the substance contains less than 3 % DMSO extract as measured by IP 346 Determination of polycyclic aromatics in unused lubricating base oils and asphaltene free petroleum fractions — Dimethyl sulphoxide extraction refractive index method, Institute of Petroleum, London. This note applies only to certain complex oil-derived substances in Part 3. Note M: The classification as a carcinogen need not apply if it can be shown that the substance contains less than 0,005 % w/w benzo[a]-pyrene (EINECS No 200-028-5). This note applies only to certain complex coal-derived substances in Part 3. Note N: The classification as a carcinogen need not apply if the full refining history is known and it can be shown that the substance from which it is produced is not a carcinogen. This note applies only to certain complex oil-derived substances in Part 3. Note P: The classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w benzene (EINECS No 200-753-7). When the substance is not classified as a carcinogen at least the precautionary statements (P102-)P260-P262-P301 + P310-P331 (Table 3.1) or the S-phrases (2-)23-24-62 (Table 3.2) shall apply. The classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w benzene (Einecs No 200-753-7). When the substance is not classified as a carcinogen at least the precautionary statements (P102-)P260-P262-P301 + P310-P331 shall apply. This note applies only to certain complex oil-derived substances in Part 3. Note Q: The classification as a carcinogen need not apply if it can be shown that the substance fulfils one of the following conditions: a short term biopersistence test by inhalation has shown that the fibres longer than 20 μm have a weighted half-life less than 10 days; or a short term biopersistence test by intratracheal instillation has shown that the fibres longer than 20 μm have a weighted half-life less than 40 days; or an appropriate intra-peritoneal test has shown no evidence of excess carcinogenicity; or absence of relevant pathogenicity or neoplastic changes in a suitable long term inhalation test. Note R: The classification as a carcinogen need not apply to fibres with a length weighted geometric mean diameter less two standard geometric errors greater than 6 μm. Note S: This substance may not require a label according to Article 17 (see section 1.3 of Annex I) (Table 3.1). This substance may not require a label according to Article 23 of Directive 67/548/EEC (see section 8 of Annex VI to that Directive) (Table 3.2). This substance may not require a label according to Article 17 (see Section 1.3 of Annex I) (Table 3). Note T: This substance may be marketed in a form which does not have the physical hazards as indicated by the classification in the entry in Part 3. If the results of the relevant method or methods in accordance with Part 2 of Annex I of this Regulation show that the specific form of substance marketed does not exhibit this physical property or these physical hazards, the substance shall be classified in accordance with the result or results of this test or these tests. Relevant information, including reference to the relevant test method(s) shall be included in the safety data sheet. Note U (Table 3.1): Note U (Table 3): When put on the market gases have to be classified as Gases under pressure, in one of the groups compressed gas, liquefied gas, refrigerated liquefied gas or dissolved gas. The group depends on the physical state in which the gas is packaged and therefore has to be assigned case by case. The following codes are assigned: Press. Gas (Comp.) Press. Gas (Liq.) … 80 unchanged lines … 3. PART 3: HARMONISED CLASSIFICATION AND LABELLING TABLE Table 3.1: List of harmonised classification and labelling of hazardous substances. Table 3.2: The list of harmonised classification and labelling of hazardous substances from Annex I to Directive 67/548/EEC. Table 3.1 Table 3 List of harmonised classification and labelling of hazardous substances Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Converted acute toxicity point estimate according to Table 3.1.2 of Annex I. Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) 001-001-00-9 hydrogen 215-605-7 1333-74-0 Flam. Gas 1 Press. Gas H220 GHS02 GHS04 … 928 unchanged lines … GHS09 Dgr H300 H410 M=100 006-046-00-8 bendiocarb (ISO); 2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate 245-216-8 22781-23-3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * 2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate; 2,2-dimethyl-1,3-benzodioxol-4-yl methylcarbamate 245-216-8 22781-23-3 Acute Tox. 3 Acute Tox. 3 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H312 H311 H300 H400 H410 GHS06 GHS09 Dgr H331 H301 H312 H410 006-047-00-3 bufencarb (ISO); H311 H300 H410 M = 10 M = 100 006-047-00-3 bufencarb (ISO); reaction mass of 3-(1-methylbutyl)phenyl N-methylcarbamate and 3-(1-ethylpropyl)phenyl N-methylcarbamate — 8065-36-9 Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 … 1,484 unchanged lines … H315 H318 H412 014-044-00-3 3-[(4'-acetoxy-3'-methoxyphenyl) propyl]trimethoxysilane 433-050-0 — Aquatic Chronic 2 H411 GHS09 H411 014-045-00-9 magnesium sodium fluoride silicate 442-650-1 — STOT RE 2 * H373** GHS08 Wng H373** 014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuationand rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08 Wng H373** 014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process.(Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08 Dgr H350i A 014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08 Wng H351 (inhalation) A … 5,360 unchanged lines … H410 047-002-00-8 polyphosphoric acid, copper, sodium, magnesium, calcium, silver and zinc salt 416-850-4 — Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), Wng H410 047-003-00-3 silver zinc zeolite (Zeolite, LTA framework type, surface-modified with silver and zinc ions) [This entry covers LTA (Linde Type A) framework type zeolite which has been surface-modified with both silver and zinc ions at contents Ag+ 0,5 %-6 %, Zn2 + 5 %-16 %, and potentially with phosphorus, NH4+, Mg2+ and/or Ca2+ each at level < 3 %] — 130328-20-0 Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H315 H318 H400 H410 GHS08 GHS05 GHS09 Dgr H361d H315 H318 H410 M = 100 M = 100 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * … 230 unchanged lines … H361fd H330 H372 ** H410 050-001-00-5 tin tetrachloride; H410 048-012-00-5 cadmium carbonate 208-168-9 513-78-0 Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 GHS08 GHS07 GHS09 Dgr H350 H340 H332 H312 H302 H372 (kidney, bone) H410 A1 048-013-00-0 cadmium hydroxide; cadmium dihydroxide 244-168-5 21041-95-2 Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 GHS08 GHS07 GHS09 Dgr H350 H340 H332 H312 H302 H372 (kidney, bone) H410 A1 048-014-00-6 cadmium nitrate; cadmium dinitrate 233-710-6 10325-94-7 Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 GHS08 GHS07 GHS09 Dgr H350 H340 H332 H312 H302 H372 (kidney, bone) H410 Carc. 1B; H350: C ≥ 0,01 % A1 050-001-00-5 tin tetrachloride; stannic chloride 231-588-9 7646-78-8 Skin Corr. 1B Aquatic Chronic 3 H314 H412 GHS05 … 391 unchanged lines … H301 H311 H372 (nervous system, immune system) H314 EUH071 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B H314 EUH071 050-030-00-3 dibutyltin dilaurate; dibutyl[bis(dodecanoyloxy)]stannane 201-039-8 77-58-7 Muta. 2 Repr. 1B STOT RE 1 H341 H360FD H372 (immune system) GHS08 Dgr H341 H360FD H372 (immune system) 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B Aquatic Chronic 2 H314 H411 GHS05 GHS09 … 5,056 unchanged lines … H411 GHS07 GHS09 Wng H315 H411 604-001-00-2 phenol; H411 603-235-00-2 linalool; 3,7-dimethyl-1,6-octadien-3-ol; dl-linalool; [1] coriandrol; (S)-3,7-dimethyl-1,6-octadien-3-ol; d-linalool; [2] licareol; (R)-3,7-dimethyl-1,6-octadien-3-ol; l-linalool [3] 201-134-4 [1] 204-810-7 [2] 204-811-2 [3] 78-70-6 [1] 126-90-9 [2] 126-91-0 [3] Skin Sens. 1B H317 GHS07 Wng H317 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 … 573 unchanged lines … GHS08 Dgr H228 H361f *** H302 604-057-00-8 reaction mass of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6 401-680-5 — Aquatic Chronic 2 H411 GHS09 H411 604-058-00-3 1,2-bis(3-methylphenoxy)ethane 402-730-9 54914-85-1 Aquatic Acute 1 H302 604-057-00-8 reaction mass of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6 401-680-5 — Aquatic Chronic 4 H413 H413 604-058-00-3 1,2-bis(3-methylphenoxy)ethane 402-730-9 54914-85-1 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 604-059-00-9 2-n-hexadecylhydroquinone 406-400-5 — STOT RE 2 * … 250 unchanged lines … Dgr H360F H314 H410 M = 10 M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B M = 10 604-093-00-4 clorofene; chlorophene; 2-benzyl-4-chlorophenol 204-385-8 120-32-1 Carc. 2 Repr. 2 Acute Tox. 4 Skin Irrit. 2 Skin Sens. 1 Eye Dam. 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H332 H315 H317 H318 H373 (kidney) H400 H410 GHS08 GHS05 GHS07 GHS09 Dgr H351 H361f H332 H315 H317 H318 H373 (kidney) H410 M = 1 M = 100 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* … 244 unchanged lines … H334 H317 H410 EUH071 STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1 605-023-00-5 5-chloro-2-(4-chlorophenoxy)phenol 429-290-0 3380-30-1 Eye Dam. 1 M = 1 605-023-00-5 5-chloro-2-(4-chlorophenoxy)phenol; [DCPP] 429-290-0 3380-30-1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H318 H400 H410 GHS05 GHS09 Dgr H318 H410 605-024-00-0 2-bromo-5-hydroxy-4-methoxybenzaldehyde 426-540-0 2973-59-3 Skin Sens. 1 H410 M = 10 M = 10 605-024-00-0 2-bromo-5-hydroxy-4-methoxybenzaldehyde 426-540-0 2973-59-3 Skin Sens. 1 Aquatic Chronic 2 H317 H411 GHS07 GHS09 … 477 unchanged lines … H411 GHS05 GHS09 Dgr H318 H411 606-041-00-6 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one 400-600-6 71868-10-5 Acute Tox. 4 * Aquatic Chronic 2 H302 H411 GHS07 H411 606-041-00-6 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one 400-600-6 71868-10-5 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 H360FD H302 H411 GHS08 GHS07 GHS09 Wng H302 Dgr H360FD H302 H411 606-042-00-1 acetophenone 202-708-7 98-86-2 Acute Tox. 4 * Eye Irrit. 2 H302 H319 GHS07 … 486 unchanged lines … H372: C ≥ 5 % STOT RE 2; H373: 0,5 % ≤C<5 % M = 10000 avermectin B1a (purity ≥80 %); [2] 265-610-3 [2] 65195-55-3 [2] M = 10000 avermectin B1a (purity ≥ 80 %); [2] 265-610-3 [2] 65195-55-3 [2] 606-144-00-6 acequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 Skin Sens. 1 STOT SE 1 … 49 unchanged lines … H373 (eyes, kidneys, liver) H317 H410 M = 100 M = 10 607-001-00-0 formic acid ... % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 M = 10 606-150-00-9 clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloroallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-one — 99129-21-2 Acute Tox. 4 Skin Sens. 1 Aquatic Chronic 3 H302 H317 H412 GHS07 Wng H302 H317 H412 EUH066 606-151-00-4 anthraquinone 201-549-0 84-65-1 Carc. 1B H350 GHS08 Dgr H350 607-001-00-0 formic acid ... % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % … 1,311 unchanged lines … H315 H317 D 607-123-00-4 2,3-epoxypropyl methacrylate; glycidyl methacrylate 203-441-9 106-91-2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 H332 H312 glycidyl methacrylate 203-441-9 106-91-2 Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 1 Eye Dam. 1 Skin Corr. 1C Skin Sens. 1 H350 H341 H360F H311 H302 H319 H315 H317 GHS07 Wng H332 H312 H335 H372 (respiratory tract) (inhalation) H318 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H360F H311 H302 H319 H315 H335 H372 (respiratory tract) (inhalation) H314 H317 D 607-124-00-X 2-hydroxyethyl methacrylate 212-782-2 868-77-9 Eye Irrit. 2 Skin Irrit. 2 … 3,526 unchanged lines … H317 GHS08 GHS07 Dgr H360D H317 608-001-00-3 acetonitrile; H317 607-720-00-X nonadecafluorodecanoic acid; [1] ammonium nonadecafluorodecanoate; [2] sodium nonadecafluorodecanoate [3] 206-400-3 [1] 221-470-5 [2] [3] 335-76-2 [1] 3108-42-7 [2] 3830-45-3 [3] Carc. 2 Repr. 1B Lact. H351 H360Df H362 GHS08 Dgr H351 H360Df H362 607-721-00-5 N,N′-methylenedimorpholine; N,N′-methylenebismorpholine; [formaldehyde released from N,N′-methylenebismorpholine]; [MBM] 227-062-3 5625-90-1 Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Skin Sens. 1 Eye Dam. 1 H350 H341 H332 H312 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H318 GHS08 GHS07 GHS05 Dgr H350 H341 H332 H312 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 EUH071 8 9 607-722-00-0 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; epsilon-momfluorothrin — 1065124-65-3 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H371 (nervous system) H400 H410 GHS07 GHS08 GHS09 Wng H302 H371 (nervous system) H410 M = 100 M = 100 607-723-00-6 tefluthrin (ISO); 2,3,5,6-tetrafluoro-4-methylbenzyl (1RS,3RS)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropanecarboxylate — 79538-32-2 Acute Tox. 1 Acute Tox. 2 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 H330 H310 H300 H400 H410 GHS06 GHS09 Dgr H330 H310 H300 H410 M = 10000 M = 10000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * … 452 unchanged lines … H318 H317 H411 608-055-00-8 fipronil (ISO); 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile — 120068-37-3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * (±)-5-amino-1-(2,6-dichloro-α,α,α-trifluoro-para-tolyl)-4-trifluoromethylsulfinyl-pyrazole-3-carbonitrile 424-610-5 120068-37-3 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H331 Aquatic Chronic 1 H301 H311 H301 H372** H331 H372* H400 H410 GHS06 GHS08 GHS09 Dgr H331 Dgr H301 H311 H301 H372** H410 M=10 608-056-00-3 N-methyl-N-cyanomethylmorpholiniummethylsulfate 429-340-1 — Acute Tox. 4 * H331 H372* H410 M = 1000 M = 10000 608-056-00-3 N-methyl-N-cyanomethylmorpholiniummethylsulfate 429-340-1 — Acute Tox. 4 * Eye Dam. 1 H302 H318 GHS05 GHS07 … 4,241 unchanged lines … H335 H315 H411 612-150-00-X spiroxamine (ISO); 8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine — 118134-30-8 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * 8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine — 118134-30-8 Repr. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 Aquatic Chronic 1 H361d H332 H312 H302 H373 (eye) H315 H317 H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H332 Wng H361d H332 H312 H302 H373 (eye) H315 H317 H410 612-151-00-5 methyl-phenylene diamine; H410 M = 100 M = 100 612-151-00-5 methyl-phenylene diamine; diaminotoluene; [technical product – reaction mass of 4-methyl-m-phenylene diamine (EC No 202-453-1) and 2-methyl-m-phenylene diamine (EC No 212-513-9)] — — Carc. 1B Muta. 2 … 1,277 unchanged lines … H373 (liver) H317 H410 M = 1 M = 1 613-001-00-1 ethyleneimine; M = 1 612-290-00-1 reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2); [formaldehyde released from 3,3′-methylenebis[5-methyloxazolidine]; formaldehyde released from oxazolidin]; [MBO] — — Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 3 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 H350 H341 H332 H311 H302 H373 (gastrointestinal tract, respiratory tract) H314 H318 H317 H411 GHS08 GHS06 GHS05 GHS09 Dgr H350 H341 H332 H311 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H411 EUH071 8 9 612-291-00-7 reaction products of paraformaldehyde with 2-hydroxypropylamine (ratio 1:1); [formaldehyde released from α,α,α-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol]; [HPT] — — Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 H350 H341 H332 H302 H373 (gastrointestinal tract, respiratory tract) H314 H318 H317 H411 GHS08 GHS07 GHS05 GHS09 Dgr H350 H341 H332 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H411 EUH071 8 9 612-292-00-2 methylhydrazine 200-471-4 60-34-4 Carc. 1B H350 GHS08 Dgr H350 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B … 2,656 unchanged lines … Wng H361d H302 H410 M = 1 M = 1 613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate - 473798-59-3 Aquatic Chronic 2 H411 GHS09 H411 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1B M = 1 613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2,3-dihydro-2-isopropyl-3-oxo-4-(o-tolyl)pyrazole-1-carbothioate; S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydropyrazole-1-carbothioate — 473798-59-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1B Acute Tox. 4 Skin Corr. 1C H360D H302 H314 GHS08 GHS07 GHS05 Dgr H360D H302 H314 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 10 M = 10 614-001-00-4 nicotine (ISO); 3-(N-methyl-2-pyrrolidinyl)pyridine 200-193-3 54-11-5 Acute Tox. 1 Acute Tox. 3 * Aquatic Chronic 2 H310 M = 10 613-321-00-1 (RS)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; medetomidine — 86347-14-0 Acute Tox. 2 Acute Tox. 2 STOT SE 3 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H300 H336 H370 (eye) H372 H400 H410 GHS06 GHS08 GHS09 Dgr H330 H300 H336 H370 (eye) H372 H410 M = 1 M = 100 613-322-00-7 triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; α-tert-butyl-β-(4-chlorophenoxy)-1H-1,2,4-triazole-1-ethanol 259-537-6 55219-65-3 Repr. 1B Lact. Acute Tox. 4 Aquatic Chronic 2 H360 H362 H302 H411 GHS08 GHS07 GHS09 Dgr H360 H362 H302 H411 613-323-00-2 terbuthylazine (ISO); N-tert-butyl-6-chloro-N′-ethyl-1,3,5-triazine-2,4-diamine 227-637-9 5915-41-3 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 H410 M = 10 M = 10 613-324-00-8 quinolin-8-ol; 8-hydroxyquinoline 205-711-1 148-24-3 Repr. 1B Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H301 H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H360D H301 H318 H317 H410 M = 1 M = 1 613-325-00-3 thiacloprid (ISO); (Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide; {(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide — 111988-49-9 Carc. 2 Repr. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 H351 H360FD H332 H301 H336 H400 H410 GHS08 GHS06 GHS09 Dgr H351 H360FD H332 H301 H336 H410 M = 100 M = 100 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 H330 H310 H300 H411 GHS06 GHS09 Dgr H310 H301 H411 614-002-00-X salts of nicotine — — Acute Tox. 2 * Dgr H330 H310 H300 H411 inhalation: ATE = 0.19 mg/L (dusts or mists) dermal: ATE = 70 mg/kg oral: ATE = 5 mg/kg 614-002-00-X salts of nicotine — — Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 H330 … 413 unchanged lines … H334 EUH014 Eye Irrit.; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % 615-013-00-2 cyanamide; carbanonitril 206-992-3 420-04-2 Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 H301 H312 H319 H315 H317 GHS06 Dgr H301 H312 H319 H315 H317 615-014-00-8 tris(1-dodecyl-3-methyl-2-phenylbenzimidazolium)hexacyanoferrate — 7276-58-6 Acute Tox. 4 * H302 GHS07 carbamonitril 206-992-3 420-04-2 Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 2 Skin Corr. 1 Skin Sens. 1 Eye Dam. 1 Aquatic Chronic 3 H351 H361fd H311 H301 H373 (thyroid) H314 H317 H318 H412 GHS08 GHS06 GHS05 Dgr H351 H361fd H311 H301 H373 (thyroid) H314 H317 H412 615-014-00-8 tris(1-dodecyl-3-methyl-2-phenylbenzimidazolium)hexacyanoferrate — 7276-58-6 Acute Tox. 4 * H302 GHS07 Wng H302 615-015-00-3 1,7,7-trimethylbicyclo(2,2,1)hept-2-yl thiocyanatoacetate; isobornyl thiocyanoacetate 204-081-5 115-31-1 Acute Tox. 4 * Aquatic Acute 1 … 304 unchanged lines … H411 616-005-00-1 chlorthiamid (ISO); 2,6-dichloro (thiobenzamide) 217-637-7 1918-13-4 Acute Tox. 4 * H302 GHS07 Wng H302 616-006-00-7 dichlofluanid (ISO); N-dichlorofluoromethylthio-N',N'-dimethyl-N-phenylsulfamide 214-118-7 1085-98-9 Acute Tox. 4 * N-[(dichlorofluoromethyl)thio]-N′,N′-dimethyl-N-phenylsulfamide 214-118-7 1085-98-9 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 H332 H319 H317 H400 GHS07 GHS09 Wng H332 H319 H317 H400 M=10 616-007-00-2 diphenamid (ISO); H400 M = 10 616-007-00-2 diphenamid (ISO); N,N-dimethyl-2,2-diphenylacetamide 213-482-4 957-51-7 Acute Tox. 4 * Aquatic Chronic 3 H302 H412 GHS07 … 479 unchanged lines … H411 GHS07 GHS09 Wng H317 H411 616-094-00-7 3,3'-dicyclohexyl-1,1'-methylenebis(4,1-phenylene)diurea 406-370-3 58890-25-8 Skin Sens. 1 Aquatic Chronic 4 H317 H413 GHS07 Wng H317 H413 616-095-00-2 3,3'-dioctadecyl-1,1'-methylenebis(4,1-phenylene)diurea 406-690-3 43136-14-7 Aquatic Chronic 4 H413 — H413 616-096-00-8 N-(3-hexadecyloxy-2-hydroxyprop-1-yl)-N-(2-hydroxyethyl)palmitamide 408-110-4 110483-07-3 Aquatic Chronic 4 H413 — H413 616-097-00-3 N,N'-1,4-phenylenebis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamide 411-840-6 83372-55-8 Aquatic Chronic 4 H413 — H413 616-098-00-9 1-[4-chloro-3-((2,2,3,3,3-pentafluoropropoxy)methyl)phenyl]-5-phenyl-1H-1,2,4-triazole-3-carboxamide 411-750-7 119126-15-7 Aquatic Chronic 2 H411 GHS09 H411 616-099-00-4 2-[4-[(4-hydroxyphenyl)sulfonyl]phenoxy]-4,4-dimethyl-N-[5-[(methylsulfonyl)amino]-2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]phenyl]-3-oxopentanamide 414-170-2 135937-20-1 Aquatic Chronic 4 H413 — H413 616-100-00-8 1,3-dimethyl-1,3-bis(trimethylsilyl)urea 414-180-7 10218-17-4 Acute Tox. 4 * H411 616-094-00-7 3,3′-dicyclohexyl-1,1′-methylenebis(4,1-phenylene)diurea 406-370-3 58890-25-8 Aquatic Chronic 4 H413 H413 616-095-00-2 3,3'-dioctadecyl-1,1'-methylenebis(4,1-phenylene)diurea 406-690-3 43136-14-7 Aquatic Chronic 4 H413 — H413 616-096-00-8 N-(3-hexadecyloxy-2-hydroxyprop-1-yl)-N-(2-hydroxyethyl)palmitamide 408-110-4 110483-07-3 Aquatic Chronic 4 H413 — H413 616-097-00-3 N,N'-1,4-phenylenebis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamide 411-840-6 83372-55-8 Aquatic Chronic 4 H413 — H413 616-098-00-9 1-[4-chloro-3-((2,2,3,3,3-pentafluoropropoxy)methyl)phenyl]-5-phenyl-1H-1,2,4-triazole-3-carboxamide 411-750-7 119126-15-7 Aquatic Chronic 2 H411 GHS09 H411 616-099-00-4 2-[4-[(4-hydroxyphenyl)sulfonyl]phenoxy]-4,4-dimethyl-N-[5-[(methylsulfonyl)amino]-2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]phenyl]-3-oxopentanamide 414-170-2 135937-20-1 Aquatic Chronic 4 H413 — H413 616-100-00-8 1,3-dimethyl-1,3-bis(trimethylsilyl)urea 414-180-7 10218-17-4 Acute Tox. 4 * Skin Irrit. 2 H302 H315 GHS07 Wng H302 … 545 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E M = 1 616-221-00-6 hexaflumuron (ISO); 1-(3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl)-3-(2,6-difluorobenzoyl)urea 401-400-1 86479-06-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1000 M = 10000 616-222-00-1 penthiopyrad (ISO); (RS)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxamide — 183675-82-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 616-223-00-7 carbetamide (ISO); (R)-1-(ethylcarbamoyl)ethyl carbanilate; (2R)-1-(ethylamino)-1-oxopropan-2-yl phenylcarbamate 240-286-6 16118-49-3 Carc. 2 Repr. 1B Acute Tox. 4 Aquatic Chronic 2 H351 H360D H302 H411 GHS08 GHS07 GHS09 Dgr H351 H360D H302 H411 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 … 761 unchanged lines … Dgr H350 H 648-082-00-2 Tar, coal, high-temp.; Coal tar; [The condensation product obtained by cooling, to approximately ambient temperature, the gas evolved in the high temperature (greater than 700 oC (1292 oF)) destructive distillation of coal. A black viscous liquid denser than water.Composed primarily of a complex mixture of condensed ring aromatic hydrocarbons. May contain minor amounts of phenolic compounds and aromatic nitrogen bases.] 266-024-0 65996-89-6 Carc. 1A H350 GHS08 [The condensation product obtained by cooling, to approximately ambient temperature, the gas evolved in the high temperature (greater than 700 oC (1292 oF)) destructive distillation of coal. A black viscous liquid denser than water. Composedprimarily of a complex mixture of condensed ring aromatic hydrocarbons. May contain minor amounts of phenolic compounds and aromatic nitrogen bases.] 266-024-0 65996-89-6 Carc. 1A H350 GHS08 Dgr H350 H 648-083-00-8 Tar, coal, low-temp.; Coal oil; … 421 unchanged lines … Dgr H350 H340 H J 648-151-00-7 Gasoline, coal solvent extn., hydrocracked naphtha; [Motor fuel produced by the reforming of the refined naphtha fraction of the products of hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boilingin the range of approximately 30 oC to 180 oC (86 oF to 356 oF). Composed primarily of aromatic and naphthenic hydrocarbons, their alkyl derivatives and alkyl hydrocarbons having carbon numbers in the range of C4 through C9.] 302-691-7 94114-55-3 Carc. 1B H350 GHS08 [Motor fuel produced by the reforming of the refined naphtha fraction of the products of hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gasextraction processes and boiling in the range of approximately 30 oC to 180 oC (86 oF to 356 oF). Composed primarily of aromatic and naphthenic hydrocarbons, their alkyl derivatives and alkyl hydrocarbons having carbon numbers in the range of C4 through C9.] 302-691-7 94114-55-3 Carc. 1B H350 GHS08 Dgr H350 H 648-152-00-2 Distillates (coal), solvent extn., hydrocracked middle; [Distillate obtained from the hydrocracking of coal extract or solution produced by the liquid solvent extraction or supercritical gas extraction processes and boiling in the range of approximately 180 °C to 300 °C (356 °F to 572 °F. Composed primarily of two-ring aromatic, hydrogenated aromatic and naphthenic compounds, their alkyl derivatives and alkanes having carbon numbers predominantly in the range of C9 through C14. Nitrogen, sulfur and oxygen-containing compounds are also present.] 302-692-2 94114-56-4 Carc. 1B … 202 unchanged lines … Dgr H350 H 649-049-00-5 Petroleum; Crude oil; [A complex combination of hydrocarbons, It consists predominantly of aliphatic, alicyclic and aromatic hydrocarbons. It may also contain small amounts of nitrogen, oxygen and sulfur compounds. This category encompasses light, medium, and heavy petroleums, as well as the oils extended from tar sands. Hydrocarbonaceous materials requiring major chemical changes for theirrecoveryor conversion to petroleum refinery feedstocks such as crude shale oils; upgraded shale oils and liquid coal fuels are not included in this definition.] 232-298-5 8002-05-9 Carc. 1B H350 GHS08 [A complex combination of hydrocarbons, It consists predominantly of aliphatic, alicyclic and aromatic hydrocarbons. It may also contain small amounts of nitrogen, oxygen and sulfur compounds. This category encompasses light, medium, and heavy petroleums, as well as the oils extended from tar sands. Hydrocarbonaceous materialsrequiring major chemical changes for theirrecovery or conversion to petroleum refinery feedstocks such as crude shale oils; upgraded shale oils and liquid coal fuels are not included in this definition.] 232-298-5 8002-05-9 Carc. 1B H350 GHS08 Dgr H350 H 649-050-00-0 Distillates (petroleum), light paraffinic; Unrefined or mildly refined baseoil; … 1,375 unchanged lines … H340 K U 649-165-00-6 Tail gas (petroleum), catalytic hydrodesulfurized naphtha separator; Refinery gas; [A complex combination of hydrocarbons obtained from thehydrodesulfurization of naphtha. It consists of hydrogen, methane, ethane, and propane.] 273-173-5 68952-79-4 Press. Gas [A complex combination of hydrocarbons obtained fromthe hydrodesulfurization ofnaphtha. It consists of hydrogen, methane, ethane, and propane.] 273-173-5 68952-79-4 Press. Gas Flam. Gas 1 Carc. 1A Muta. 1B H220 … 1,293 unchanged lines … H304 H P 649-314-00-5 Hydrocarbons, C5-11, nonaroms.-rich, reforming light fraction; Low boiling point cat-reformed naphtha; [A complex combination of hydrocarbons obtained by separation from the platformate-containing fraction. It consists predominantly of nonaromatic hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling in the range of approximately 35 °C to 125 °C (94 °F to 257 °F), benzene and toluene.] 297-466-2 93572-36-2 Carc. 1B [A complex combination of hydrocarbons obtained by separation from the platformate-containing fraction. It consists predominantly of nonaromatic hydrocarbons having carbon numbers predominantly in the range of C5 through C11 and boiling inthe range of approximately 35 °C to 125 °C (94 °F to 257 °F), benzene and toluene.] 297-466-2 93572-36-2 Carc. 1B Muta. 1B Asp. Tox. 1 H350 H340 … 979 unchanged lines … Dgr H304 H 649-431-00-1 Distillates (petroleum), hydrodesulfurized full-range middle coker; Kerosine — unspecified; [A complex combination of hydrocarbons obtained by fractionation from hydrodesulfurized coker distillate. It consists predominantly of hydrocarbons having carbonnumbers predominantly in the range of C8 through C16 and boiling in the range of approximately 120 oC to 283 oC (248 oF to 541 oF).] 309-864-6 101316-58-9 Asp. Tox. 1 H304 GHS08 [A complex combination of hydrocarbons obtained by fractionation from hydrodesulfurized coker distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C8 through C16 and boiling in the range of approximately 120 oC to 283 oC (248 oF to 541 oF).] 309-864-6 101316-58-9 Asp. Tox. 1 H304 GHS08 Dgr H304 H 649-432-00-7 Solvent naphtha (petroleum), hydrodesulfurized heavy arom.; Kerosine — unspecified; … 619 unchanged lines … Wng H302 H373 ** H317 H410 650-032-00-X cyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H—1,2,4-triazol-1-yl)butan-2-ol — 94361-06-5 Repr. 2 Acute Tox. 4 * H410 650-032-00-X cyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol — 94361-06-5 Repr. 1B Acute Tox. 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361d *** H302 Aquatic Chronic 1 H360D H301 H373 (liver) H400 H410 GHS08 GHS07 GHS09 Wng H361d *** H302 H410 650-033-00-5 (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate; GHS06 GHS09 Dgr H360D H301 H373 (liver) H410 M = 10 M = 1 650-033-00-5 (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate; esfenvalerate — 66230-04-4 Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 … 7,694 unchanged lines … Xn; R48/20: 0,5% ≤ C <5% N; R50-53: C ≥ 0,0025% N; R51-53: 0,00025% ≤ C<0,0025% R52-53: 0,000025% ≤ C<0,00025% avermectin B1a (purity ≥80%); [2] 265-610-3 [2] 65195-55-3 [2] R52-53: 0,000025% ≤ C<0,00025% avermectin B1a (purity ≥ 80%); [2] 265-610-3 [2] 65195-55-3 [2] 606-144-00-6 acequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 T; R39/23 Xi; R43 … 12,167 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61